Premium versus standard intraocular lenses for cataracts a review of clinical effectiveness and cost-effectiveness
Because of the potential benefits that premium intraocular lenses (IOLs) may offer, alongside the potential for increased expense on the part of the patient and/or third-party payers, evidence is needed to inform decision-making. This report aims to synthesize available evidence on the comparative c...
| Main Authors: | , , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
[Ottawa]
Canadian Agency for Drugs and Technologies in Health
2018, June 18, 2018
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Because of the potential benefits that premium intraocular lenses (IOLs) may offer, alongside the potential for increased expense on the part of the patient and/or third-party payers, evidence is needed to inform decision-making. This report aims to synthesize available evidence on the comparative clinical effectiveness and cost-effectiveness of premium compared with standard monofocal IOLs for patients with cataracts |
|---|---|
| Physical Description: | 1 PDF file (42 pages) illustration |